Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Hematology & Oncology Physician in Chicago, IL
NPI: 1316906779Primary Practice Location
NORTHWESTERN MEMORIAL HOSPITAL
250 E Superior St, Chicago, IL
Primary Employer
Northwestern Medical Group
nm.org
HQ Phone
Get M.D. Jamile's Phone Numberphone_androidMobile
Get M.D. Jamile's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
IL State Medical License
1991 - 2026
American Board of Internal Medicine
Hematology
American Board of Pathology
Anatomic Pathology & Clinical Pathology
University of Chicago
Fellowship • Hematology and Medical Oncology
1996 - 1999
McGaw Medical Center of Northwestern University
Residency • Internal Medicine
1991 - 1995
University of Chicago (Endeavor Health – NorthShore Hospitals)
Residency • Pathology-Anatomic and Clinical
1988 - 1991
University of Aleppo Faculty of Medicine
Medical School
Until 1985
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 44 | 64 |
| 2 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 34 | 34 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 31 | 63 |
| 4 | 99204New patient office or other outpatient visit, 45-59 minutes | 26 | 26 |
| 5 | 96372Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | 20 | 29 |
The May-Hegglin anomaly: a rare cause of a common complaint
Authors: Priyanka Reddy, Revathi Kollipara, Jamile M. Shammo, Jerome Loew
Publication Date: 2021-03
Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma.
Authors: Reem Karmali, Stephanie Gregory
Publication Date: 2016-08-29
Lead Sponsor: Traws Pharma, Inc.
Intervention / Treatment: DRUG: Azacitidine, DRUG: oral rigosertib
Lead Sponsor: Astex Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: ASTX727, DRUG: Dacogen
Lead Sponsor: Traws Pharma, Inc.
Intervention / Treatment: DRUG: best supportive care (BSC), DRUG: rigosertib, DRUG: Any approved or standard-of-care therapy
